New therapeutic target in Alzheimer’s disease identifiedApril 14th, 2009 - 1:21 pm ICT by ANI
Washington, April 14 (ANI): Researchers at University College London (UCL) have identified a protein, known as serum amyloid P component (SAP), which may be a possible therapeutic target in Alzheimer’s disease.
Lead researchers Professor Mark Pepys FRS has even developed a new small molecule drug, CPHPC, which specifically targets SAP and removes it from the blood.
Working in collaboration with Professor Martin Rossor from the Dementia Research Centre of UCL’s Institute of Neurology, Professor Pepys’ team have also shown that the drug also removes SAP from the brains of patients with Alzheimer’s disease.
During a study, the researchers gave the drug to 5 Alzheimer’s disease patients for 3 months, and found SAP to deplete not only from the subjects’ blood but from their brains also.
Lab tests revealed the molecular mechanism responsible for the unique effect, and also disclosed for the first time the way in which SAP accumulates in the brain in Alzheimer’s disease.
The researchers revealed that neither the administration of CPHPC nor the removal of SAP had any side effects in the patients.
“The safety of CPHPC, together with the novel action of the drug in removing SAP from the brain, is very encouraging”, said Professor Rossor.
Although the 3-month treatment period was too short to show any clinical benefit, there was no obvious deterioration.
The researchers are planning longer and larger scale clinical studies to confirm safety and seek evidence of benefit to the patients.
“The complete disappearance of SAP from the brain during treatment with CPHPC could not have been confidently predicted, and the drug, also to our surprise, entered the brain. Coupled with the absence of any side effects, these new findings strongly support further clinical studies to see whether longer term treatment with CPHPC protects against the inexorable mental decline in patients with Alzheimer’s disease,” said Professor Pepys.
The study has been published in the PNAS. (ANI)
- Tobacco-derived compound prevents memory loss in Alzheimer's - Apr 28, 2011
- Insulin could play powerful role in fighting Alzheimer's - Apr 02, 2011
- Potent new vaccine found effective against Alzheimer's - Jun 08, 2012
- Drug reversing Alzheimer's symptoms found - Feb 12, 2012
- Drug reverses Alzheimer's symptoms in mice: Study - Feb 10, 2012
- New brain imaging technique shows effects of Parkinson's drug - Dec 01, 2010
- New drug limits brain damage in stroke - Jul 27, 2012
- Blood test to detect Alzheimer's disease in offing - Aug 10, 2012
- Antihypertensive drugs may offer protection against Alzheimer's - Jun 24, 2010
- Delivering drugs directly to brain may help Alzheimer's sufferers - Mar 21, 2011
- Why Alzheimer's drug is both safe and effective - Aug 19, 2010
- Bilingualism can delay onset of Alzheimer's symptoms by 5 yrs: Study - Nov 09, 2010
- Bilingualism can delay onset of Alzheimer's symptoms: Study - Nov 10, 2010
- 5 more genes behind Alzheimer's disease risk identified - Apr 04, 2011
- Alzheimer's drugs may have serious side-effects - Feb 20, 2012
Tags: april 14, clinical benefit, cphpc, dementia, dementia research centre, deterioration, disappearance, disease patients, lab tests, mental decline, molecular mechanism, molecule, pepys, professor mark, professor martin, sap, therapeutic target, treatment period, ucl, university college london